SCHEMBL20959611

SCHEMBL20959611

O=C(N[C@@H]1CCC(F)(F)C[C@@H]1C(=O)O)OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CPB1 P15086 2/20 0.54
ALDH1A1 P00352 2/20 0.52
GAA P10253 1/20 0.52
KDM1A O60341 1/20 0.49
MAOB P27338 1/20 0.49
CASP3 P42574 3/20 0.48
CYP1A2 P05177 1/20 0.47
TSHR P16473 1/20 0.47
DPP4 P27487 1/20 0.46
KCNH2 Q12809 1/20 0.46
DPP7 Q9UHL4 1/20 0.46
EPHX1 P07099 1/20 0.44
CTSB P07858 3/20 0.44
CTSK P43235 3/20 0.44
CTSS P25774 2/20 0.44
CTSL P07711 2/20 0.44
TACR1 P25103 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28517210 1.00 CPB1 (0.54) CPB1ALDH1A1GAAKDM1AMAOB
SCHEMBL28380648 0.88 CPB1 (0.54) CPB1ALDH1A1GAAKDM1AMAOB
SCHEMBL1770076 0.88 CPB1 (0.54) CPB1ALDH1A1GAAKDM1AMAOB
SCHEMBL26632495 0.84 CPB1 (0.52) CPB1ALDH1A1GAAKDM1AMAOB
SCHEMBL31405400 0.84 CPB1 (0.52) CPB1ALDH1A1GAAKDM1AMAOB
SCHEMBL7434389 0.84 CPB1 (0.52) CPB1ALDH1A1GAAKDM1AMAOB
SCHEMBL28376797 0.83 CPB1 (0.47) CPB1ALDH1A1GAAKDM1AMAOB
SCHEMBL28380419 0.83 CPB1 (0.47) CPB1ALDH1A1GAAKDM1AMAOB
SCHEMBL3063260 0.83 CPB1 (0.72) CPB1ALDH1A1GAACASP3CYP1A2
SCHEMBL579214 0.83 CPB1 (0.72) CPB1ALDH1A1GAACASP3CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10435399-B2 HDAC6 inhibitory heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-10-08 US disclosed
US-20190135799-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435399-B2 HDAC6 inhibitory heterocyclic compound HDAC6, HDAC1, HDAC5 CPB1 4168/4885ALDH1A1 400/4885GAA 191/4885
US-20190135799-A1 HETEROCYCLIC COMPOUND HDAC1, HDAC5, HDAC6 CPB1 4037/4885ALDH1A1 417/4885GAA 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.